for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

LeMaitre Vascular Inc

LMAT.OQ

Latest Trade

35.20USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

21.79

 - 

38.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
35.20
Open
--
Volume
--
3M AVG Volume
2.19
Today's High
--
Today's Low
--
52 Week High
38.99
52 Week Low
21.79
Shares Out (MIL)
19.85
Market Cap (MIL)
698.61
Forward P/E
41.14
Dividend (Yield %)
0.97

Next Event

LeMaitre Vascular Inc at Sidoti & Company Fall Conference

Latest Developments

More

Lemaitre Vascular Q2 Earnings Per Share $0.23

Lemaitre Vascular Reports Q1 Earnings Per Share $0.17

Lemaitre Vascular Q4 Earnings Per Share $0.30

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About LeMaitre Vascular Inc

LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company's product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.

Industry

Medical Equipment & Supplies

Contact Info

63 2nd Ave

+1.781.2212266

http://www.lemaitre.com/

Executive Leadership

George W. LeMaitre

Chairman of the Board, Chief Executive Officer

David Brian Roberts

President, Director

Joseph P. Pellegrino

Chief Financial Officer, Director

Laurie A. Churchill

Senior Vice President, General Counsel

Andrew Hodgkinson

Senior Vice President - Clinical, Regulatory and Quality Affairs

Key Stats

2.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

0.550

2017

0.860

2018

1.130

2019(E)

0.856
Price To Earnings (TTM)
38.55
Price To Sales (TTM)
6.32
Price To Book (MRQ)
5.05
Price To Cash Flow (TTM)
29.95
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
13.73
Return on Equity (TTM)
12.33

Latest News

BRIEF-LeMaitre Vascular Q1 Earnings Per Share $0.19

* Q1 EARNINGS PER SHARE VIEW $0.21 -- THOMSON REUTERS I/B/E/S

BRIEF-Lemaitre Vascular Divests General Surgery Product Lines

* DIVESTED GENERAL SURGERY PRODUCT LINES TO SYMMETRY SURGICAL FOR $7.4 MILLION Source text for Eikon: Further company coverage:

BRIEF-LeMaitre Vascular Q4 Earnings Per Share $0.21

* SEES Q1 2018 SALES $26.0 MILLION- $26.6 MILLION; FY 2018 SALES $110.0 MILLION - $111.6 MILLION

BRIEF-Lemaitre Vascular sees ‍Q4 sales of $25.8 mln

* Lemaitre Vascular Inc - qtrly sales of $24.8 million, up 7% from Q3 2016

BRIEF-Lemaitre sees 2017 earnings per diluted share $0.79

* Lemaitre Q2 2017 record sales $25.8 mm (+15%), record EPS $0.23 (+69%)

BRIEF-LeMaitre Vascular Inc Q1 earnings per share $0.16

* LeMaitre Q1 2017 record sales $24.1 mm (+19%), net income $3.2 mm (+49%)

BRIEF-Lemaitre sees q2 earnings per share $0.70

* Lemaitre q1 2017 record sales $24.1 mm (+19%), net income $3.2 mm (+49%)

BRIEF-Lemaitre Vascular Q4 earnings per share $0.13

* Q4 earnings per share view $0.15 -- Thomson Reuters I/B/E/S

BRIEF-Lemaitre Vascular acquires Restore Flow Allografts

* Lemaitre Vascular Inc- expects acquisition to increase Q4 and full-year 2016 revenues by $550,000 and to reduce Q4 and full-year 2016 operating income by $200,000

BRIEF-Lemaitre Vascular Q3 EPS $0.17

* Q3 earnings per share view $0.15 -- Thomson Reuters I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up